Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. - Wikidata - awgldk - TriplyDB

Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori.

Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori.

http://www.wikidata.org/entity/Q44371256

about

Optimum duration of regimens for Helicobacter pylori eradication New concepts of resistance in the treatment of Helicobacter pylori infections Systematic review: third-line susceptibility-guided treatment for Helicobacter pylori infection Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection CYP2C19 polymorphism influences Helicobacter pylori eradication Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment.Treatment of Helicobacter pylori infection: current status and future concepts.Facing resistance of H.pylori infection Clinical practice: diagnosis and evaluation of dyspepsia.High-dose extended-release lansoprazole (dexlansoprazole) and amoxicillin dual therapy for Helicobacter pylori infections Treatment of Helicobacter pylori infection: Past, present and future CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials.Pharmacogenomics of adverse drug reactions: practical applications and perspectives.Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy.Influence of inflammatory cytokine polymorphisms on eradication rates of Helicobacter pylori.Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective.Effect of bacterial and host factors on Helicobacter pylori eradication therapy Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature.Efficacy of esomeprazole in treating acid-related diseases in Japanese populations High-dose esomeprazole and amoxicillin dual therapy for first-line Helicobacter pylori eradication: a proof of concept study.Efficacy and safety of high dose dual therapy for Helicobacter pylori rescue therapy: A systematic review and meta-analysis.Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects.Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice.Hybrid Therapy Regimen for Helicobacter Pylori Eradication Efficacy of Levofloxacin Based Triple and High-Dose PPI-Amoxicillin Dual Eradication Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies.Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics.Tailored Therapy Versus Empiric Chosen Treatment for Helicobacter pylori Eradication: A Meta-Analysis Efficient identification and evaluation of effective Helicobacter pylori therapies.DNA variations in human and medical genetics: 25 years of my experience.CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.Cost-effectiveness analysis in pharmacogenomics.Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.Current pharmacotherapy options for gastritis.Current options for the treatment of Helicobacter pylori.A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication).Culture-guided treatment approach for Helicobacter pylori infection: review of the literature.Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype.Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance.Challenges to the Treatment and New Perspectives for the Eradication of Helicobacter pylori.

P2860

Q24201841-57E1D3C6-8EDE-4237-B12A-E3BD7AC534C6 Q24622513-568A9AD8-0703-446A-9E46-BA82A0986403 Q26745727-C7141C8C-C0AA-47B9-92F0-8BC22C05D425 Q26853010-3ECD98D8-325B-4A93-B663-4C8CA7C534E1 Q27005916-1631576B-52E8-431B-B315-F6FB9ABB3749 Q31144283-396D6000-8569-467B-9EEE-DC88A272BD65 Q33594850-5AB7164A-2862-4BD0-BCCC-562865D659CA Q33596218-AF29CA24-F415-4DCF-BF91-B05E3C55041F Q33687928-C079F00D-9D4C-4293-BC61-DC259B5E8ED1 Q33953262-FE197F16-2820-40B8-9650-5AD0CAD6396C Q34508830-32821F16-743D-41CB-B14D-E1BF4911538E Q34583603-0C20B22D-C478-4447-B159-55FB0C63B6C3 Q34706721-644AB1D8-C970-4143-B8DD-8A309CB76ADF Q34987138-E069C02A-BB70-480F-A8E1-FFEF4E7B37E2 Q35056670-51F22E3C-D496-4B25-A48E-9C01E4B0AFD7 Q35082607-873C1268-FE85-48D6-987E-E4818341D327 Q35598058-1115A0D7-52D9-4974-A113-A4A1DD216D51 Q35738262-F695DBB9-54A2-4B8F-9C61-04550FE15024 Q35890606-2EE1E4A1-6DAD-48A0-B224-CA3B873E7DFE Q35987201-C10C088A-160E-4AAA-AEE5-9ABCFCAA9337 Q36098476-8A38EF9B-71F0-405F-8B12-30A2C3A99106 Q36224538-66A87DF3-C529-49B7-9D61-F2C9760598D3 Q36475190-5A9C2C7C-73A6-4210-BEDA-CDFE9595F6A4 Q36702588-E56B5AAD-44B8-49AB-BA17-9A94CD90EA6E Q36797844-77896C05-3982-44F4-9EEF-85E8037A0542 Q36979151-48DF08FA-C1A5-4EF7-80A2-C16A67FA6540 Q36979297-93A8652A-1BD1-4670-B08C-A6741BBDD4B8 Q37206124-7EE57764-8763-4706-8E70-9AD42A38542F Q37332276-02BACE29-ACC9-4E99-8D5F-8C8C21DE7F0C Q37374228-1B67BE88-C957-41C4-8F64-72CFED628D3F Q37646785-CC187862-AD75-4192-BF25-45A9EF6187C3 Q37736459-C4CEB571-CE5F-4D11-AC92-76236B27FCC5 Q38032920-7DDFE5BE-5918-4849-B786-2D65C3CA4425 Q38061147-C4828033-A4FC-4B88-AE2A-05749F813FE9 Q38075061-89883026-B754-4650-BFCF-3B3BBAE4C3A6 Q38093864-DF95F198-01D0-4D62-A2B3-873A992CA76C Q38212210-06B919E4-2CD5-4517-AB0B-924E0A23E02C Q38219028-92448046-4D3C-4D92-9B74-0520006CE71C Q38238745-D89F3809-04F3-47B9-A35E-EF9BD09C1A12 Q38496942-47069434-2FFC-48B1-9DD9-824EFEFFC22A

P2860

Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori.

http://www.wikidata.org/entity/Q44371256

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Pharmacogenomics-based tailore ...... for eradication of H. pylori.

@en

Pharmacogenomics-based tailore ...... for eradication of H. pylori.

@nl

type

label

Pharmacogenomics-based tailore ...... for eradication of H. pylori.

@en

Pharmacogenomics-based tailore ...... for eradication of H. pylori.

@nl

prefLabel

Pharmacogenomics-based tailore ...... for eradication of H. pylori.

@en

Pharmacogenomics-based tailore ...... for eradication of H. pylori.

@nl

P1433

Q44371256-837632CF-6C6A-4B05-833C-7118FB9D754D

P1476

Q44371256-FC4257A5-3148-47DF-8C90-08A4B461E5CE

P2093

Q44371256-08F4690A-CE26-4C53-A617-680726EB11E7

Q44371256-37A0FAB4-4FB1-455E-86CF-FE57FAB6AC16

Q44371256-435A6C3A-949B-4AE0-BD8D-019A1AE69587

Q44371256-58455A0C-DDA6-4A1D-B67B-A4816095C2AF

Q44371256-6DA41603-B1B2-4D7F-AF65-B7A987D6C455

Q44371256-6ED7802C-2982-46AD-96B2-23240C992ECA

Q44371256-75660A87-424D-4119-966B-7A7A7A076E1F

Q44371256-7B8EA0B5-DF84-4264-9158-0E817C068DE1

Q44371256-B4498165-99EA-4BB9-8BAC-E3FDA11A79B5

Q44371256-BE8DD97C-6BDB-41CD-A3E6-1984991793DD

P2860

Q44371256-0592EA3B-503C-495D-A2D4-2498085D3BCD

Q44371256-1602ABF2-D835-46A0-B11E-2AB049F9CE24

Q44371256-1EB5381F-9537-4802-AD9D-59DDE1A194B6

Q44371256-21C3CF43-A242-4D86-9DE2-49A072F11B6D

Q44371256-2877E665-3749-4661-AE8A-7A23523FDC62

Q44371256-2AA5BC1B-0018-481A-B3F8-86CA5D738736

Q44371256-360AD5FC-A8AD-4AB5-B0AF-C6EFF58AFC1B

Q44371256-420A9E58-25F1-474E-B0D5-0E68488BC9F1

Q44371256-596E1060-5F99-483C-A0E9-8CB3F65B219F

Q44371256-5FCC249F-84A2-46F7-A2EF-3BC3DCE496B4

P2888

Q44371256-734D8D27-322A-47AC-9DCE-5B034CD6475D

P304

Q44371256-6F7E086C-F378-46BF-9980-2221CA5B90AF

P31

Q44371256-E852A241-3F16-48C8-A99F-921C78480E53

P356

Q44371256-A7CC6483-824A-48F0-8891-03983F56F913

P407

Q44371256-87A00A7C-9988-417B-89E9-193CF85112F3

P433

Q44371256-84F1C072-141E-454E-A4E7-51E0F079E08E

P478

Q44371256-9FC2EB07-C33E-40AE-9DEB-D47C2791FDB3

P577

Q44371256-F0D8ACE6-5154-4803-985C-0F57BD8A52CE

P6179

Q44371256-9D2A81EB-54C9-4697-AC43-2F3E599B0FBE

P698

Q44371256-48D6606F-E8EA-4CD3-B6BB-D98F110D3F9E

P921

Q44371256-127B2D8F-8000-4B0B-80E3-67F005377D1A

Q44371256-30373393-A15F-4494-9E9B-1FA2F68001A1

P356

SJ.CLPT.6100043

P1433

Clinical Pharmacology & Therapeutics

P1476

Pharmacogenomics-based tailore ...... for eradication of H. pylori.

@en

P2093

A Hishida

http://www.w3.org/2001/XMLSchema#string

A Nogaki

http://www.w3.org/2001/XMLSchema#string

I Terakawa

http://www.w3.org/2001/XMLSchema#string

K Ohashi

http://www.w3.org/2001/XMLSchema#string

M Iwaizumi

http://www.w3.org/2001/XMLSchema#string

M Kodaira

http://www.w3.org/2001/XMLSchema#string

M Sugimoto

http://www.w3.org/2001/XMLSchema#string

M Yamade

http://www.w3.org/2001/XMLSchema#string

N Shirai

http://www.w3.org/2001/XMLSchema#string

S Kuriyama

http://www.w3.org/2001/XMLSchema#string

P2860

H pylori antibiotic resistance: prevalence, importance, and advances in testing

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese

Helicobacter pylori infection and the development of gastric cancer

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.

Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19

Pharmacogenomics of proton pump inhibitors.

A systematic review of cost-effectiveness analyses of pharmacogenomic interventions.

Drug metabolism and variability among patients in drug response.

Sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction.

P2888

sj.clpt.6100043

P304

521-528

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.CLPT.6100043

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

81

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1026987713

http://www.w3.org/2001/XMLSchema#string

P698

17215846

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics

Helicobacter pylori